Life Science Investor Relations Forum (EXL) 2017 | ExL Events, Inc. | 7 September 2017 | Revere Hotel Boston Common  , 200 Stuart Street, Boston, Massachusetts 02116, United States

The Life Science Investor Relations Forum, taking place on September 7—8, 2017 in Boston, will bring together IR professionals to address the diverse set of challenges faced in the life sciences industry. Our expert speaking faculty will provide thought-provoking dialogue paired with networking opportunities that no other conferences address. IR teams are continuously balancing new regulations, advancements in technology, more engaged investors and working relationships with advisory boards. Through this event IR specialists will be able to efficiently gain the knowledge they need to improve their programs while developing a new network of educated IR colleagues. At this breakthrough, two-day conference we will provide our attendees with the solutions to the unique set of challenges IR teams encounter and enable them to be more effective in their jobs.

Seth Lewis
Vice President Investor Relations
Bavarian Nordic A/S

Christine Regan Lindenboom
Vice President, Investor Relations and Corporate Communications
Alnylam Pharmaceuticals

Michelle Linn,
Vice President Corporate Communications
Agenus

Sara Pelleegrino
Senior Director, Investor Relations
Amicus Therapeutics

Salim Syed,
Managing Director, Senior Biotechnology Analyst, Head of Biotechnology Research
Mizuho Securities USA

Mark Vignola
Director, Investor Relations
Intercept Pharmaceuticals

Felicia Vonella
Executive Director, Investor Relations
Acorda Therapeuutics